The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-line (1L) trastuzumab deruxtecan (T-DXd) with volrustomig and fluoropyrimidine in patients with HER2-low gastric cancer (GC), gastroesophageal junction adenocarcinoma (GEJA), or esophageal adenocarcinoma (EA): DESTINY-Gastric03 (DG-03) part 5.
 
Yelena Janjigian
Stock and Other Ownership Interests - Inspirna; OncoDaily; Veda Life Sciences
Honoraria - Abbvie; AmerisourceBergen; Arcus Biosciences; AskGene Pharma; Astellas Pharma; AstraZeneca; Basilea Pharmaceutical; Bayer; BeOne; Boehringer Ingelheim; Bristol-Myers Squibb; Clinical Care Options; Daiichi Sankyo; eChinaHealth; Ed Med Resources (OncInfo); Eisai; Geneos; Genzyme; Gilead Sciences; GlaxoSmithKline; Guardant Health; H.C. Wainwright & Co.; HMP Education; i3 Health; i3 Health; IDEOlogy Health; Imedex; Imugene; Inspirna; Lilly; Lynx Health; Master Clinician Alliance; Merck; Merck Serono; Mersana; Michael J. Hennessy Associates; Paradigm; Peerview; Pfizer; Physicians' Education Resource, LLC; Regeneron; Research to Practice; Seagen; Silverback Therapeutics; Suzhou Liangyihui Network Technology; Talem Health; TotalCME; WebMD; Zymeworks
Consulting or Advisory Role - Abbvie; AmerisourceBergen; Arcus Biosciences; AskGene Pharma; Astellas Pharma; AstraZeneca; Basilea Pharmaceutical; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Clinical Care Options; Daiichi Sankyo; Debbies Dream Foundation; Ed Med Resources (OncLive); Eisai; Geneos; Genzyme; GlaxoSmithKline; GlaxoSmithKline; Guardant Health; H.C. Wainwright & Co.; HMP Education; Imedex; Imugene; Inspirna; Jazz Pharmaceuticals; Lilly; Lynx Health; Merck; Merck Serono; Mersana; Michael J. Hennessy Associates; OncoDaily; Paradigm; Peerview; Pfizer; Physicians' Education Resource, LLC; Research to Practice; Seagen; Signatera; Silverback Therapeutics; WebMD; Zymeworks
Research Funding - Arcus Biosciences (Inst); Astellas Pharma; AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Cycle for Survival (Inst); Department of Defense (Inst); Fred's Team (Inst); Genentech/Roche (Inst); Inspirna (Inst); Lilly (Inst); Merck (Inst); NCI (Inst); Stand up to Cancer (Inst); Transcenta (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb Japan; Merck
Other Relationship - Axis Medical Education; Clinical Care Options; Giants of Cancer Care; Research to Practice
 
Hanneke Van Laarhoven
Consulting or Advisory Role - Amgen (Inst); Amphera (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Daiichi (Inst); MSD Oncology (Inst); MyeoloidTx (Inst)
Speakers' Bureau - AstraZeneca (Inst); BMS (Inst); CongressCare (Inst); Daiichy Sankyo (Inst); MedTalks (Inst); Travel Congress Management (Inst); Uitgeverij Jaap (Inst)
Research Funding - Amgen (Inst); Auristone; BMS (Inst); Incyte (Inst); Merck KGaA (Inst); ORCA Therapeutics (Inst); Servier (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Roy Rabbie
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Caron Lloyd
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Zhuoer Sun
Employment - AstraZeneca
 
Jeeyun Lee
Consulting or Advisory Role - Amgen; AstraZeneca; Daichi Sankyo; Guardant Health AMEA; Immunoncia; Mirati Therapeutics; Trutino Biosciences
Research Funding - AstraZeneca; Merck Sharp & Dohme; Samsung Biopeis; Samsung Biopeis